Brought to you by 
Second Genome raises $42.6mm through oversubscribed Series B round; SR One invests additional $8.4mm
25 Jul 2016
Executive Summary
Pfizer Venture Investments and Roche Venture Fund co-led a $42.6mm Series B round for Second Genome Inc. (microbiome-based drug discovery for GI and metabolic diseases). The investors also take board seats. Additional participants in the oversubscribed round included new buyers Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and the Mayo Clinic, along with Series A investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, PhD.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Second Genome raises $42.6mm through oversubscribed Series B round; SR One invests additional $8.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice